Study on Fecal Microbiota Transfer for Preventing Recurrent Urinary Tract Infections in Premenopausal Women Using Intestifix

2 1 1

What is this study about?

This clinical trial is focused on studying the effectiveness of a treatment called fecal microbiota transfer (FMT) for preventing recurrent urinary tract infections (rUTI) in premenopausal women. Recurrent urinary tract infections are infections that happen frequently, causing symptoms like pain during urination, frequent urination, or pain in the lower back. The study aims to see if FMT can help reduce the number of these infections by introducing healthy bacteria from a donor’s stool into the patient’s gut, which may help restore a healthy balance of bacteria.

The trial will compare the effects of FMT with other treatments, including Monuril 3000 mg Granulat, which contains the active ingredient fosfomycin trometamol, and Vancomycin, an antibiotic. Additionally, a product called INTESTIFIX 001, derived from donor stool, will be used. Some participants will receive a placebo, which looks like the real treatment but does not contain the active ingredients. The study will monitor participants over a period to see how many new urinary tract infections occur and how quickly they happen after treatment.

Throughout the study, participants will be observed for any changes in their symptoms and overall quality of life. The trial will also assess the safety of FMT by reviewing any side effects or new medical conditions that arise during the follow-up period. The goal is to understand how effective FMT is in preventing recurrent urinary tract infections and to identify factors that contribute to its success.

1 joining the trial

Upon joining the trial, you will be asked to provide written informed consent. This means you agree to participate after understanding the trial’s purpose and procedures.

You must meet certain criteria, such as being a premenopausal adult woman with a history of recurrent urinary tract infections (rUTI).

2 initial assessment

An initial assessment will be conducted to confirm your eligibility. This includes reviewing your medical history and any recent urinary tract infections.

A urinary culture may be performed to ensure the infection is caused by bacteria susceptible to the study medication.

3 treatment phase

During the treatment phase, you may receive a fecal microbiota transfer (FMT) to help prevent future urinary tract infections.

You will also be given medications such as Monuril 3000 mg Granulat and Vancomycin, both taken orally. The specific dosage and frequency will be explained by the study team.

4 follow-up visits

You will have follow-up visits on Day 7, 30, 90, and 180 after the treatment to monitor your health and any symptoms.

During these visits, your quality of life and any changes in symptoms will be assessed.

5 monitoring and reporting

Throughout the trial, you will be asked to report any new urinary tract infections or other health issues.

The study team will monitor your condition and any side effects from the treatment.

6 end of trial

The trial will conclude after 180 days of follow-up. Your participation will help assess the effectiveness of the treatment in preventing recurrent urinary tract infections.

You will receive a final assessment to review your overall health and any outcomes from the trial.

Who Can Join the Study?

Must be a premenopausal adult woman. This means a woman who has not yet gone through menopause.
Must have a recent history of recurrent urinary tract infections (rUTI), defined as having four or more urinary tract infections in the last 12 months. A urinary tract infection is when you have at least one typical symptom like painful urination, frequent urination, or pain in the side, without other causes.
Must have tried and not succeeded with lifestyle changes to prevent rUTI, such as drinking more water and urinating after sex.
The last urinary tract infection must have been confirmed by a urine test and caused by bacteria called Escherichia coli or Klebsiella pneumoniae that can be treated with a specific antibiotic called fosfomycin.
Must be able to give written informed consent, which means you understand the study and agree to participate according to international and local laws.
Must be able to understand the nature of the trial and follow the trial procedures.

Who Cannot Join the Study?

Patients who are male cannot participate in the study.
Patients who are under the age of 18 cannot participate in the study.
Patients who are part of a vulnerable population cannot participate. This means groups of people who might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Universitaetsklinikum Schleswig-Holstein AöR	Kiel	Germany
Gfaemg Upoeuvpugf Fcgfixwff	Frankfurt	Germany
Uavuciccwx Hofazbnt Cyofwqy	Cologne	Germany

Trial status

Country	Status	Recruitment Start
Germany	Recruiting	01.09.2025

Trial locations

Investigated drugs:

Fecal Microbiota Transfer (FMT) is a therapy that involves taking healthy bacteria from the stool of a donor and transferring it to the intestines of a patient. The goal of this treatment is to restore the natural balance of bacteria in the patient’s gut. In this clinical trial, FMT is being tested to see if it can help prevent recurrent urinary tract infections in premenopausal women. By introducing healthy bacteria, the therapy aims to strengthen the body’s natural defenses against infections.

Investigated diseases:

Urinary tract infection

Recurrent urinary tract infections (rUTI) – Recurrent urinary tract infections are characterized by multiple episodes of infection in the urinary tract, which includes the bladder, urethra, ureters, and kidneys. These infections are typically caused by bacteria, most commonly Escherichia coli, that enter the urinary tract. Symptoms often include a strong, persistent urge to urinate, a burning sensation during urination, and cloudy or strong-smelling urine. In some cases, individuals may experience pelvic pain or flank pain. The condition is more common in women than men, due to anatomical differences. Recurrent infections can lead to discomfort and may require ongoing management to prevent further episodes.

Trial ID:

2025-520452-28-00

Protocol code:

FEMITRANS

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Fecal Microbiota Transfer for Preventing Recurrent Urinary Tract Infections in Premenopausal Women Using Intestifix

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?